expert reaction to 6-month follow up of phase 2 trial of psilocybin versus escitalopram for depression
A follow up of a phase 2 trial published in eClinicalMedicine looks at the effect of psilocybin versus escitalopram for depression. … read more
A follow up of a phase 2 trial published in eClinicalMedicine looks at the effect of psilocybin versus escitalopram for depression. … read more
A study published in The BMJ looks at a clinical trial of esketamine for mothers with prenatal depression symptoms. Dr Camilla … read more
A study published in The New England Journal of Medicine looks at a trial of Lixisenatide in early Parkinson’s Disease. Professor … read more
It has been announced that the National Cancer Research Institute (NCRI) is closing down. Professor Nick James, Professor of … read more
The review by Lord O’Shaughnessy has been published as part of the package of announcements on life sciences growth in … read more
A conference abstract (not a published paper) presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2022 compares the … read more
Results of the phase 3 trial of lecanemab for early Alzheimer’s disease has been published in New England Journal of … read more
Roche have announced that the results of their phase 3 trial evaluating gantenerumab in people with early Alzheimer’s disease did … read more
An abstract (not a published paper) presented at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, … read more
A report published by the ABPI (Association of the British Pharmaceutical Industry) suggests a drop in number of industry clinical … read more
Results from a phase 1 trial looking at tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine have been published … read more
A press release from Eisai and Biogen has announced positive topline results from their Phase 3 clinical trial of lecanemab … read more
Around 5,000 people in the UK have motor neurone disease (MND) – also known as amyotrophic lateral sclerosis (ALS). Two … read more
Results of a phase 3 clinical trial looking at the use of tofersen for motor neurone disease (MND) has been … read more
University of Oxford researchers have been running trials of their R21/Matrix-M malaria vaccine candidate in children in Burkina Faso, Africa. … read more
Results of the phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21, in … read more
Since May this year we have seen numerous outbreaks of monkeypox outside the countries where it has been endemic. This … read more
Results from a phase 1 clinical trial looking at the use of low-dose subcutaneous or intravenous monoclonal antibody to prevent … read more
A preprint, an unpublished non peer reviewed study, gives the results of the baricitinib arm of the RECOVERY trial. This … read more
Since March 2020, the University of Oxford-led RECOVERY trial has been testing a range of potential treatments for patients hospitalised … read more